SWAG Cancer Alliance 2020/21 Funding Profile and Deliverables

SWAG Cancer Alliance 2020/21 Funding Profile and Deliverables

To support delivery of the recovery priorities for cancer set out in the Phase 3 letter to the system. Service Development Funding has been split between general place-based funding and specific funding for: Rapid Diagnostic Centres (RDCs); Targeted Lung Health Checks (TLHC) projects (NA SWAG); Colon Capsule Endoscopy (CCE); and new additional funding to support local innovation. Some small reductions have been made to the funding levels compared to previously-communicated 2020/21 allocations. These take account of the impact that COVID-19 has had on Long Term Plan delivery and spend in the first half of 2020/21, but recognise the costs Alliances have incurred in recovery efforts, and in particular the acceleration of RDC delivery. Please note: Cancer Alliances can use their general place-based funding flexibly according to local need. General place-based funding includes funding to support a Cancer Alliance core team. Funding set out here will include some level of allocations already in the system. Further supporting information regarding the transaction and access to allocations in the months October 2020-March 2021 will follow in due course. The primary purpose of the RDC funding must be for RDC delivery, and Cancer Alliances are expected to use this funding to accelerate implementation of RDCs to support recovery. Where it is considered that no further meaningful investment in RDCs can be made within this financial year, funding can be used to support other projects to support recovery. This must be clearly recorded in Cancer Alliance planning and reporting returns. Funding for TLHC projects New Innovation Funding, calculated on a population basis, has been made available to all Cancer Alliances to fund the adoption and retention of local innovations to support the response to COVID-19.

Full-year 2020/21 funding levels SWAG Total general SDF allocation 20/21 ( m) (including core team) Rapid Diagnostic Centres ( m) Colon capsule Endoscopy ( m) Innovation Funding ( m) Total 4.202 2.59 0.26 0.19 7.24 Cancer Alliance core Team - 0.573 Total 3.629 2.59 0.26 0.19 6.669

Service Development Funds Working Assumptions Q1 and Q2 SDF already in system in block contracts and calculated from M9 2019/20 We are working with our host CCG (BNSSG) and finance colleagues at Regional level to determine monies available to systems and Alliance for months 7-12

Cross Cutting Enablers Alliance SDF 000 TBC Support recovery with Alliance working through and with systems COVID responses e.g. FIT Clinical Leadership* TBC Image Sharing TBC Early diagnosis LTP ambition screening uptake NHS E Screening Plan TBC Treatment - Continue to support establishment of radiotherapy networks Infrastructure TBC Treatment - Genomics Infrastructure TBC Treatment - Support trusts to implement the recommendations of the GIRFT lung cancer audit, to reduce variation in access to and outcome of lung cancer treatment TBC Total from SDF

2020/21 Deliverables Recovery Restore urgent cancer referrals at least to pre-pandemic levels. Reduce the backlog at least to pre-pandemic levels on 62 day (urgent referral and referral from screening) and 31 day pathways. Ensure sufficient capacity to manage increased demand moving forward including follow-up care. Ensure that polyp surveillance guidance has been fully implemented, to support endoscopy recovery. Audit the implementation of timed diagnostic pathways (lung, prostate, colorectal and oesophago-gastric cancers) and continue to drive their delivery where this aligns with struggling pathways and aids recovery. Earlier and Faster Diagnosis Early diagnosis LTP ambition. RDCs should build on 19/20 requirements and support Covid-19 recovery by delivering an RDC pathway for one challenged two-week wait pathway with a focus on pathways key to recovery (with 50% of GPs actively referring in) and a non-specific symptoms pathway for at least 20% of people see next slide . By April 2021, all trusts to routinely offer the three main personalised care interventions (Personalised Care and Support Planning; Health and Wellbeing Information and Support; End of Treatment Summary) for breast, prostate and colorectal patients, and ensure other cancer types will rapidly follow (April 2022 at the latest) Personalised Care Approximately two-thirds of patients who finish treatment for breast cancer to be on a supported self-management follow-up pathway. By April 2021, all trusts to have clinically agreed personalised stratified follow up protocols in operation for colorectal and prostate cancer. Implementation of digital RMS should follow as soon as possible (April 2022 at the latest). Cancer Alliances can plan to roll out Personalised Stratified Follow Up (PSFU) to other cancer types from this year, with a view to having in place at least five cancer types by 2023/24. This is in addition to the existing requirement for PSFU for breast, prostate and colorectal. Cancer Alliances can plan to roll out Personalised Stratified Follow Up (PSFU) to other cancer types from this year, with a view to having in place at least five cancer types by 2023/24. This is in addition to the existing requirement for PSFU for breast, prostate and colorectal. The Cancer Quality of Life (QoL) Survey will be live from September 2020. A central comms pack is available and Cancer Alliances LWBC Leads should use this to help promote the survey across their Alliance. Treatment Continue to support establishment of radiotherapy networks. Support implementation of the C/TYA service specifications. Support roll out of more extensive genomic testing to patients who are newly diagnosed with cancers so that by 2023 over 100,000 people a year can access these tests. Support roll out of whole genome sequencing for patients with cancer, including children. Support trusts to implement the recommendations of the GIRFT lung cancer audit, to reduce variation in access to and outcome of lung cancer treatment.

RDC Funding Profile 2.59 Plans and allocations approved March 2020 board

Supporting Objectives 000 Source Tackling inequalities, including where they may have been further impacted by the COVID-19 pandemic 0 Ensuring that patients and staff have confidence that services are COVID-protected 0 Ensuring we have the right workforce in place 0.2 Additional HEE funding* Ensuring effective communications across the wider cancer community 0 Locking in innovations prompted by the pandemic or which support recovery - GENERAL 0.193 Additional - not SDF - allocations to be agreed** Locking in innovations prompted by the pandemic or which support recovery - COLON CAPSULE ENDOSCOPY 0.26 Additional - not SDF X1 Clinic per Alliance***

Governance Systems to provide the cancer Alliance with plans for each deliverable (slide 6) Plans approved and MoUs will agreed to include reporting schedules Exception report to Board

LTP Ambitions By 2023/24: An extra 30,000 people each year will survive for five years or more, following a cancer diagnosis. Significantly more patients will be diagnosed at an early stage (stage 1 or 2) so that the NHS is on track to ensure 75% of people are diagnosed at an early stage by 2028.